IP Library › Granted Patent US 7,053,070

Granted Patent B2

US 7,053,070 · App. 10/182,178 · Granted May 30, 2006

Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors

Assignee: Warner-Lambert Company

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,053,070
App. No.: 10/182,178
Granted: May 30, 2006
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed are compounds of the formula wherein R 2 , R 5 , R 6 , R 7 , and R 8 are as defined herein. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.

Claims (211)

1. A compound of the Formula I

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:

R 2 , R 7 , R 13 , R 14 , and R 15 are independently hydrogen, or

lower alkyl, lower alkenyl, lower alkynyl, or —(CH 2 ) n R 12 each of which is optionally substituted with up to 5 groups independently selected from halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —(CH 2 ) n CO 2 R 9 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 , —COR 9 , —CONR 9 R 10 , —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

a heterocycle optionally substituted with up to 3 groups independently selected from —R 9 , —NR 9 R 10 , —OR 9 , —NR 9 COR 10 , —COR 10 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 ;

R 5 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , or —OR 9 ;

R 6 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —CO 2 R 9 , —COR 9 , —CONR 9 R 10 , —NR 9 COR 10 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , or

lower alkenyl or lower alkynyl optionally substituted with —R 9 ;

R 8 is H, —CO 2 R 13 , —COR 13 , —CONR 13 R 14 , —CSNR 13 R 14 , —C(NR 13 )NR 14 R 15 , —SO 3 R 13 , —SO 2 R 13 , —SO 2 NR 13 R 14 , —PO 3 R 13 R 14 , —POR 13 R 14 , or —PO(NR 13 R 14 ) 2 ;

R 9 and R 10 are independently hydrogen, or

lower alkyl, optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, phenyl and substituted phenyl,

or when taken together with the nitrogen to which they are attached, R 9 and R 10 form a ring having from 3-7 members, up to four of which may be selected from the group consisting of

O, S, and NR 20 , where R 20 is hydrogen, lower alkyl, or —CO lower alkyl;

R 11 is a heteroaryl or a heterocyclic group;

R 12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and

Each n is independently 0, 1, 2, or 3.

2. A compound of the Formula II

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:

R 7 , R 13 , R 14 , and R 15 are independently hydrogen, or

a heterocycle optionally substituted with up to 3 groups independently selected from —R 9 , —NR 9 R 10 , —OR 9 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 ;

R 5 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , or —OR 9 ;

R 6 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —CO 2 R 9 , —COR 9 , —CONR 9 R 10 , —NR 9 COR 10 , or

lower alkenyl or lower alkynyl optionally substituted with —R 9 ;

R 9 and R 10 are independently hydrogen, or

lower alkyl, optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, phenyl and substituted phenyl,

or when taken together with the nitrogen to which they are attached, R 9 and R 10 form a ring having from 3-7 members, up to four of which may be selected from the group consisting of

O, S, and NR 20 , where R 20 is hydrogen, lower alkyl, or —CO lower alkyl;

R 11 is a heteroaryl or a heterocyclic group;

R 12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group;

each n is independently 0, 1, 2, or 3; and

R 16 , R 17 , and R 18 are independently hydrogen, halogen, amino, mono- or dialkylamino, hydroxy, lower alkyl, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, alkylcarbonyl, —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , or —NR 9 SO 2 R 10 ; or

R 16 is a heterocyclic group containing from 3-7 members, up to 2 of which members are heteroatoms selected from oxygen and nitrogen, wherein the heterocyclic group is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of halogen, hydroxy, lower alkyl, trifluoromethyl, lower alkoxy, amino, mono- or dialkylamino, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heteroarylsulfonyl, heteroarylsulfonylalkyl, heterocyclylalkyl, heterocyclylsulfonyl, and heterocyclylsulfonylalkyl.

3. A compound of the Formula III

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:

R 2 is hydrogen, or

lower alkyl, lower alkenyl, lower alkynyl, or —(CH 2 ) n R 12 , each of which is optionally substituted with up to 5 groups independently selected from halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —(CH 2 ) n CO 2 R 9 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 , —COR 9 , —CONR 9 R 10 , —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

a heterocycle optionally substituted with up to 3 groups independently selected from —R 9 , —NR 9 R 10 , —OR 9 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 ;

R 5 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , or —OR 9 ;

R 6 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —CO 2 R 9 , —COR 9 , —CONR 9 R 10 , —NR 9 COR 10 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SO 3 R 9 , SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , or

lower alkenyl or lower alkynyl optionally substituted with —R 9 ;

R 9 and R 10 are independently hydrogen, or

lower alkyl, optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, phenyl and substituted phenyl,

or when taken together with the nitrogen to which they are attached, R 9 and R 10 form a ring having from 3-7 members, up to four of which may be selected from the group consisting of

O, S, and NR 20 , where R 20 is hydrogen, lower alkyl, or —CO lower alkyl;

R 11 is a heteroaryl or a heterocyclic group;

R 12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group;

each n is independently 0, 1, 2, or 3;

R 19 is hydrogen, or

(i) lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, lower alkylcarbonyl, —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

(ii) aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl or cycloalkyl-alkyl, where each aryl, heteroaryl or cycloalkyl group is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, alkylcarbonyl, —SO 3 R 9 , —SO 2 R 9 R 10 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

(iii) a (CH 2 ) n — heterocyclic group containing from 3-7 members, up to 2 of which members are heteroatoms selected from oxygen and nitrogen, wherein the heterocyclic group is unsubstituted or substituted with 1, 2, or 3 groups independently selected from the group consisting of halogen, hydroxy, lower alkyl, trifluoromethyl, lower alkoxy, amino, mono- or dialkylamino, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heteroarylsulfonyl, heteroarylsulfonylalkyl, heterocyclylalkyl, heterocyclylsulfonyl, and heterocyclylsulfonylalkyl; and

R 21 is hydrogen, lower alkyl, or lower alkyl substituted with phenyl or substituted phenyl.

4. A compound of the Formula IV

and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:

R 5 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , or —OR 9 ;

R 6 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —CO 2 R 9 , —COR 9 , —CONR 9 R 10 , —NR 9 COR 10 , —SO 2 R 9 R 10 , —SO 2 R 9 , —SO 3 R 9 , —SR 9 , —PO 3 R 9 R 10 , POR 9 R 10 , —PO(NR 9 R 10 ) 2 , or

lower alkenyl or lower alkynyl optionally substituted with —R 9 ;

R 9 and R 10 are independently hydrogen, or lower alkyl optionally substituted with up to 3 groups selected from the group consisting of halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, phenyl and substituted phenyl,

or when taken together with the nitrogen to which they are attached, R 9 and R 10 form a ring having from 3-7 members, up to four of which may be selected from

O, S, and NR 20 , where R 20 is hydrogen, lower alkyl, or —CO lower alkyl;

R 11 is heteroaryl or a heterocyclic group;

R 16 , R 17 , and R 18 are independently selected from halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9, —(CH 2 ) n CO 2 R 9 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 , —COR 9 , —CONR 9 R 10 , —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

a heterocycle optionally substituted with up to 3 groups independently selected from —R 9 , —NR 9 R 10 , —OR 9 , —NR 9 COR 10 , —COR 10 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 ;

R 19 is hydrogen, or

R 21 is hydrogen, lower alkyl, or lower alkyl substituted with phenyl or substituted phenyl.

5. A compound of the Formula V

and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof;

wherein:

R 5 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , or —OR 9 ;

R 6 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —CO 2 R 9 , —COR 9 , —CONR 9 R 10 , —NR 9 COR 10 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SO 3 R 9 , SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 1 O) 2 , or

lower alkenyl or lower alkynyl optionally substituted with —R 9 ;

R 16 , R 17 , and R 18 are independently selected from hydrogen, halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —(CH 2 ) n CO 2 R 9 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 , —COR 9 , —CONR 9 R 10 , —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

a heterocycle optionally substituted with up to 3 groups independently selected from —R 9 , —NR 9 R 10 , —OR 9 , —NR 9 COR 10 , —COR 10 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 ;

or when taken together with the nitrogen to which they are attached, R 9 and R 10 form a ring having from 3-7 members, up to four of which may be selected from the group consisting of

O, S, and NR 20 , where R 20 is hydrogen, lower alkyl, or —CO lower alkyl;

R 11 is heteroaryl or a heterocyclic group;

R 19 is hydrogen, or

(i) tower alkyl, lower alkenyl, or tower alkynyl, each of which is optionally substituted with up to 5 groups independently selected from halogen, amino, mono- or dialkylamino, hydroxy, lower alkoxy, cyano, nitro, carboxy, carboxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, lower alkylcarbonyl, —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

R 21 is hydrogen, lower alkyl, or lower alkyl substituted with phenyl or substituted phenyl.

6. A compound of Formula VI

and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof; wherein:

R 5 is halogen, cyano, nitro, —R 9 , —NR 9 R 10 , or —OR 9 ;

lower alkenyl or lower alkynyl optionally substituted with —R 9 ;

R 17 and R 18 are independently selected from halogen, cyano, nitro, —R 9 , —NR 9 R 10 , —OR 9 , —(CH 2 ) n CO 2 R 9 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 , —COR 9 , —CONR 9 R 10 , —SO 3 R 9 , —SO 2 NR 9 R 10 , —SO 2 R 9 , —SR 9 , —PO 3 R 9 R 10 , —POR 9 R 10 , —PO(NR 9 R 10 ) 2 , —NR 9 COR 10 , —NR 9 CO 2 R 10 , —NR 9 CONR 9 R 10 , —NR 9 SO 2 R 10 , or

a heterocycle optionally substituted with up to 3 groups independently selected from —R 9 , —NR 9 R 10 , —OR 9 , —NR 9 COR 10 , —COR 10 , —(CH 2 ) n SO 2 R 11 , —(CH 2 ) n R 11 ; and

R 22 and R 23 independently are hydrogen or alkyl.

7. A compound selected from:

1-tert-Butyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-tert-Butyl-3-[2-(3-chloro-4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-tert-Butyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-tert-Butyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-tert-butyl-urea;

1-Cyclohexyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-[2-(3-Chloro-4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexyl-urea;

1-Cyclohexyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;

1-(2-Hydroxy-ethyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-[2-(3-Chloro-4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxy-ethyl)-urea;

1-[6-Fluoro-2-(4-piperazin-1-yl)-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxy-ethyl)-urea;

1-(2-Hydroxy-ethyl)-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-(2-hydroxy-ethyl)-urea;

1-Ethyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-[2-(3-Chloro-4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-ethyl-urea;

1-Ethyl-3-[6-fluoro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Ethyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-3-chloro-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;

1-{2-[4-(4-Acetyl-piperazin-1-yl)-phenylamino]-5-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-ethyl-urea;

1-tert-Butyl-3-(2-phenylamino-pyrido[2,3-d]pyrimidin-7-yl)-urea;

1-tert-Butyl-3-[2-(4-fluoro-3-methyl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-(4-Chloro-phenyl)-3-[2-(4-fluoro-3-methyl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Isopropyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-Cyclohexyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-Cyclopentyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-Cyclopentyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-bromo-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-cyano-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-chloro-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-fluoro-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-bromo-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-chloro-5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Isopropyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Ethyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-[5-Methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Methyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-1-methyl-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-(4-Hydroxy-cyclohexyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-(4-Amino-cyclohexyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-(2-Dimethylamino-ethyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-(3-Morpholino-4-yl-propyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

3-Cyclohexyl-1-methyl-1-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

N,N-Dimethyl-N□-[5-methyl-2-[[4-(1-piperazinyl)phenyl]-amino]-pyrido[2,3-d]pyrimidin-7-yl]-sulfamide;

1-Cyclohexyl-3-[5-methyl-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-thiourea;

N-[2-(4-Piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-acetamide;

4-[7-(3-Cyclohexyl-ureido)-pyrido[2,3-d]pyrimidin-2-ylamino]-benzenesulfonamide;

1-Cyclohexyl-3-{2-[4-(1-piperazin-1-yl-methanoyl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-Cyclohexyl-3-[2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-(2-{4-[4-(2-Amino-4-methyl-pentanoyl)-piperazin-1-yl]-phenylamino}-pyrido[2,3-d]pyrimidin-7-yl)-3-cyclohexyl-urea; and

1-(2-{4-[4-(2-Amino-3-methyl-butanoyl)-piperazin-1-yl]-phenylamino}-pyrido[2,3-d]pyrimidin-7-yl)-3-cyclohexyl-urea.

8. A compound selected from:

1-tert-Butyl-3-[2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Ethyl-3-[2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-(Hydroxy-ethyl)-3-[2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-tert-Butyl-3-[6-fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[6-fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Ethyl-3-[6-fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-[6-Fluoro-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxy-ethyl)-urea;

1-tert-Butyl-3-[5-methyl-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-[5-methyl-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Ethyl-3-[5-methyl-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea; and

1-(2-Hydroxy-ethyl)-3-[5-methyl-2-(pyridin-4-ylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea.

9. A compound selected from:

4-{4-[7-(3-tert-Butyl-ureido)-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester;

4-{4-[7-(3-Cyclohexyl-ureido)-pyrido[2,3-d]pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester;

1-(3-Hydroxy-propyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-((S)-1-Hydroxymethyl-3-methyl-butyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

4-Methyl-piperazine-1-carboxylic acid [2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-amide;

Piperazine-1-carboxylic acid [2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-amide;

1-((R)-1-Hydroxymethyl-2-methyl-propyl)-3-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-[6-Bromo-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea;

1-{6-Bromo-2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-3-cyclohexyl-urea;

1-[2-(4-Fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(3-morpholin-4-yl-propyl)-urea;

1-[2-(4-Fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxy-ethyl)-urea;

1-(2-Amino-ethyl)-3-[2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-Cyclohexyl-3-{2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-fluoro-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-tert-Butyl-3-{6-chloro-2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;

3-Cyclohexyl-1-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-1-methyl-urea;

3-Cyclohexyl-1-ethyl-1-[2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

3-tert-Butyl-1-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-1-ethyl-urea;

7-(3-tert-Butyl-ureido)-2-(4-piperazin-1-yl-phenylamino)-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester;

1-Cyclohexyl-3-{2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-Cyclohexyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-methyl-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-methyl-pyrido[2,3-d]pyrimidin-7-yl}-urea;

1-tert-Butyl-3-[6-methyl-2-(4-piperazin-1-yl)-phenylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea;

1-{2-[4-(cis-3,5-Dimethyl-piperazin-1-yl)-phenylamino]-6-methyl-pyrido[2,3-d]pyrimidin-7-yl}-3-isopropyl-urea;

1-Cyclopropyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-methyl-pyrido[2,3-d]pyrimidin-7-yl}-urea; and

1-tert-Butyl-3-{2-[4-(cis-3,5-dimethyl-piperazin-1-yl)-phenylamino]-6-ethyl-pyrido[2,3-d]pyrimidin-7-yl}-urea.

10. A pharmaceutical composition comprising a compound selected from claim 1 admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

11. A method of inhibiting a cdk enzyme comprising contacting the cdk enzyme with a compound selected from claim 1 .

12. A method of claim 11 wherein said cdk is cdk1.

13. A method of claim 11 wherein said cdk is cdk2.

14. A method of claim 11 wherein said cdk is cdk4.

15. A method of inhibiting a growth factor-mediated tyrosine kinase comprising contacting said growth factor-mediated kinase with a compound selected from claim 1 .

16. A method of claim 15 wherein said growth factor-mediated tyrosine kinase is platelet derived growth factor (PDGF).

17. A method of claim 15 wherein said growth factor-mediated tyrosine kinase is fibroblast growth factor (FGF).

18. A method of treating a subject suffering from diseases caused by vascular smooth muscle cell proliferation comprising administering to said subject a therapeutically effective amount of a compound selected from claim 1 .

Continuity (2)

Provisional Application 6017826100 · Jan 25, 2000

Related Publication 20030073668A1 · Apr 17, 2003